Oncocyte Publishes Study Demonstrating Predictive Potential

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient’s response to immunotherapy...

Related Keywords

Oncocyte Determa , Neoadjuvant Immunochemotherapy , Rob Seitz , Bob Yedid , Megan Kernan , Exchange Commission , Yale University , Oncocyte Corporation , Lifesci Advisors , Oncocyte Corporation Nasdaq , Baylor University , Novel Immunomodulatory , Gene Signature , Predict Response , Primary Triple Negative Breast , Triple Negative Breast Cancer , Immune Oncology , Forward Looking , Sci Advisors , Nasdaq Ocx ,